This company is a pharmaceutical company.Making research drug to treat cystic fibrosis. This disease is caused by two recessive gene carrier getting married or giving birth a child(the child may be a sick one). Because it is carried by white. So it is mainly in western population. It is in phase 2, and it report good result. So if the phase 3 is good and get FDA approved in the future, it should be good for the company.
Technical analysis, the recent gap can be considered a 2nd gap,or measured gap. Although it get downgraded,
if there is no big market melt down and no big shock news aboult health care and the clinical trial, it should have another up leg.
This is not recommendation for buying or selling. Only for your information only. I did not hold this stock now.